相关实验视频

Updated: Jan 15, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

在复发性和耐火性多发性骨髓瘤中,每周一次对每周两次卡菲尔佐米布的比较分析:一个元分析

Wenhao Yang¹, Xiangtu Kong², Hui Yu²

¹The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.

Therapeutic advances in hematology

|October 9, 2025

概括

每周服用一次卡菲尔佐米布可以改善无进展生存率,并减少复发性或耐药性多发性骨髓瘤 (RRMM) 患者的不良事件. 这种剂量计划提供了一种潜在的更安全和更有效的替代方案,而不是每周两次治疗.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床药理学临床药理学

背景情况:

卡菲尔佐米布是复发性或耐火性多发性髓瘤 (RRMM) 的关键治疗方法.
在RRMM中卡菲尔佐米布的最佳剂量频率仍然是临床辩论的主题.
了解剂量对安全性和疗效的影响对于患者管理至关重要.

研究的目的:

在RRMM患者中,比较每周一次和每周两次使用卡菲尔佐米布剂量的安全性和有效性.
为卡菲尔佐米布 (carfilzomib) 给药时间表提供基于证据的指导.
评估不同剂量方案之间的关键疗效终点和不良事件概况.

主要方法:

进行了系统的元分析,搜索了五个主要数据库的相关研究.
计算了 95% 置信区间 (CI) 的相对风险 (RR) 和危险比率 (HR).
使用StateMP 18软件进行了统计分析,包括异质性和敏感性评估.

主要成果:

每周一次的卡菲尔佐米布显著改善了无进展生存率 (HR:0.80,95% CI:0.69-0.94,p=0.007).
在整体响应率 (RR:1.13,95% CI:0.94-1.38) 或完整响应或更好 (RR:2.08,95% CI:0.65-6.65) 中没有发现显著差异.
每周一次的计划与不良事件的减少有关 (RR:0.98,95% CI:0.96-1.00,p=0.047).

结论:

与每周两次剂量相比,每周一次的卡菲尔佐米布显示出更高的无进展生存率.
每周服用一次的疗法与良好的安全性相关,不良事件较少.
这一元分析支持每周一次的卡菲尔佐米布作为RRMM的可行和潜在的更安全的治疗选择.

关键词:

卡菲尔佐米比 (Carfilzomib) 是一种药物.进行元分析.每周一次,每周一次.复发性和耐火性多发性骨髓瘤每周两次每周两次.

更多相关视频

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...